000			02378 a2200721 4500
005			20250516190730.0
264		0	_c20151102
008			201511s 0 0 eng d
022			_a1873-7560
024	7		_a10.1016/j.eururo.2013.12.017 _2doi
040			_aNLM _beng _cNLM
100	1		_aParker, Alexander S
245	0	0	_aHigher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. _h[electronic resource]
260			_bEuropean urology _cNov 2014
300			_a929-35 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Observational Study; Research Support, N.I.H., Extramural; Validation Study
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntigens, Neoplasm _xanalysis
650	0	4	_aBiomarkers, Tumor _xanalysis
650	0	4	_aBiopsy
650	0	4	_aCarcinoma, Renal Cell _xenzymology
650	0	4	_aDNA Topoisomerases, Type II _xanalysis
650	0	4	_aDNA-Binding Proteins _xanalysis
650	0	4	_aFemale
650	0	4	_aFlorida
650	0	4	_aHumans
650	0	4	_aImmunohistochemistry
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aKidney Neoplasms _xenzymology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMinnesota
650	0	4	_aMultivariate Analysis
650	0	4	_aNecrosis
650	0	4	_aNeoplasm Grading
650	0	4	_aNeoplasm Staging
650	0	4	_aNephrectomy _xadverse effects
650	0	4	_aObserver Variation
650	0	4	_aPredictive Value of Tests
650	0	4	_aProportional Hazards Models
650	0	4	_aRegistries
650	0	4	_aReproducibility of Results
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aTertiary Care Centers
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aTumor Burden
650	0	4	_aUp-Regulation
650	0	4	_aYoung Adult
700	1		_aEckel-Passow, Jeanette E
700	1		_aSerie, Daniel
700	1		_aHilton, Tracy
700	1		_aParasramka, Mansi
700	1		_aJoseph, Richard W
700	1		_aWu, Kevin J
700	1		_aCheville, John C
700	1		_aLeibovich, Bradley C
773	0		_tEuropean urology _gvol. 66 _gno. 5 _gp. 929-35
856	4	0	_uhttps://doi.org/10.1016/j.eururo.2013.12.017 _zAvailable from publisher's website
999			_c23415185 _d23415185